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Dimethyl sulfoxide (DMSO) is the cryoprotectant of choice for most animal cell systems since the early
history of cryopreservation. It has been used for decades in many thousands of cell transplants. These
treatments would not have taken place without suitable sources of DMSO that enabled stable and safe
storage of bone marrow and blood cells until needed for transfusion. Nevertheless, its effects on cell
biology and apparent toxicity in patients have been an ongoing topic of debate, driving the search for less
cytotoxic cryoprotectants. This review seeks to place the toxicity of DMSO in context of its effectiveness.
It will also consider means of reducing its toxic effects, the alternatives to its use and their readiness for
active use in clinical settings.
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Dimethyl sulfoxide (Me2SO; commonly referred to as DMSO) has been a keystone agent in the development
of applied cryobiology over the past 50 years. The use of DMSO as a cryoprotectant capable of mitigating
freezing-related cell injuries was first documented by Lovelock and Bishop during slow cooling of bull sperm [1].
As a dipolar aprotic solvent (i.e., a solvent that cannot donate a hydrogen bond), DMSOhas an array of properties
that allow its participation in numerous chemical reactions. This chemical versatility has been studied for many
decades [2–4]. It is beyond the scope of this review to detail these and further information can be found elsewhere [5];
but in brief, the agent has strong molecular stability, a high dielectric constant, properties of basicity, solvation of
salts, particularly anions and a propensity to act as the acceptor atom in hydrogen bonding, in other words, aprotic.
From earliest studies, it was estimated that a hydrogen bond between DMSO and water is stronger by about 30%
than that between two water molecules [2]. It was also shown that DMSO could protect both against biological
injuries sustained during cryopreservation and against some aspects of radiation injury [6]. Against this backdrop of
intensive study of DMSO in the 1950’s and 1960’s, it is perhaps not so surprising that Lovelock and Bishop took
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forward studies on cryopreservation using the agent. Over the next 20 years, several comprehensive reviews on the
chemistry and pharmacology of DMSO were produced [5,7]. Readers are directed to these for further insights.
Pure DMSO is a clear colorless liquid, which crystallizes at +18.5◦C, and is hygroscopic and exothermic
when mixed with aqueous solutions. The property of strong hydrogen bonding with water imparts its antifreeze
characteristics. DMSO can readily pass through biological membranes largely with minimal evidence of injury,
has widespread solvation properties [5] and has found utility as a vehicle for clinical drug administration and
dissolving water-insoluble compounds for test systems. Metabolic products of DMSO (notably dimethyl sulfide)
frequently impart a perceived bitter taste and a breath odor similar to garlic [8], which has often raised questions
about personal acceptance of therapies involving DMSO, for example, when using the chemical as a solvent for
topical applications of different drugs. Pharmacological effects such as nephrotoxicity and ocular toxicity have been
reported in experiments where repeated high daily oral or dermal dosing was performed [5]. The impact of DMSO
in multiple organisms and biological systems has also been reported by Shu et al. [9].
Table 1 shows highlights for some of these effects. However, the direct relevance of these observations for
cryobiological applications of DMSO is questionable.
This current review will attempt to examine the evidence for and against the biological impacts of the use of
DMSO as practiced in modern cryopreservation protocols, with particular reference to clinical applications.
DMSO into cryopreservation studies
Following the report by Lovelock and Bishop [1], other contemporaneous studies were made into the cryobiological
applications of DMSO and the potential pharmacological changes of the agent under the same exposure conditions.
For example, Farrant et al. studied cryopreservation of smooth muscle preparations, and reported absence of any
specific pharmacological responses, but did note some nonspecific osmotic damage [28]. This was one of the earliest
reports to highlight one of the issues which have confused discussions about DMSO toxicity in cryopreservation
– the potential osmotic injuries incurred when loading and unloading cells and tissues with any cryoprotective
agent (CPA) – not only DMSO – in the concentrations required for cryopreservation (frequently at levels of 10%
w/v or around 1 M), versus any specific molecular alterations dependent on DMSO chemistry. In the same era,
Ashwood-Smith et al. (1964) reported successful cryopreservation by slow cooling of murine lymphocytes and
storage for 3 months at -196◦C using DMSO concentrations up to 15% (w/v) [29]. In the following years, slow
cooling cryopreservation using DMSO was applied to a range of cells (mostly blood cell subsets) and tissues [30–35].
Today hematopoietic stem cell (HSC) transplantation has become well-established procedure for treatment of many
disorders of the hematopoietic system. According to the European society of Blood and Marrow Transplantation
(EBMT) survey, in 2014 more than 40,000 transplants have been performed in European countries, with more
than 55% of them being autologous and thus requiring cryopreservation [36]. The main indications for HSC
transplantation are leukemias, lymphoid neoplasias including non-Hodgkin lymphoma (NHL), solid tumors and
nonmalignant disorders. Many of these require either autologous stem cell transplantation or umbilical cord blood
(UCB) HSC infusion after high-dose chemotherapy and require the inclusion of mandatory cryopreservation step
into the treatment protocol.
Biological & clinical impact of DMSO
Having confirmed cryoprotective properties and ensuring high viability of cells post-thaw, the direct administration
of DMSO-containing cellular products can be associated with a number of well-identified side effects and short-
comings [37]. According to the EBMT analysis, around 30–60% DMSO-containing transplants are associated with
at least one side effect or complication [38,39]. The most common are nausea, vomiting, hypertension/hypotension,
sedation or headache [38]. However, there is evidence of more serious complications such as cardiac arrhythmia,
encephalopathy, acute renal failure, bronchospasm and neurologic disorders. The direct infusion of highly osmolar
(around 1400 mOsmol for 10% DMSO, compared with ∼290 mOsm for serum) solution into the isotonic envi-
ronment such as blood, will result in the significant water uptake by the infused cells and subsequent detrimental
changes in cell homeostasis, leading to apoptosis and cell death [40]. In this case, the efficiency of the transplantation
will be significantly decreased or it will fail completely. Such observations have driven the clinical and research
institutions to search for ways of minimizing these potentially hazardous effects by either reducing the concentra-
tion of DMSO, removing the cryoprotectant from the cryopreserved cell-containing grafts prior to application (as
described in section 5 below) or replacing DMSO with an alternative cryoprotectant.
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Table 1. Examples of reported biological effects of dimethyl sulfoxide across a range of biological systems.
Cell type/line DMSO T◦C Effect Ref.
Microorganisms
Saccharomyces cerevisiae BY4743 CryoT◦ – Increasing expression of genes responsible for synthesis of proteins,
ergosterol, cell wall biosynthesis, ribosomal biosynthesis, accumulation of
low molecular weight substances (glycerol, arginine, proline)
– Downregulation of genes involved in -oxidation of fatty acids
[10]
Stem cells
Human embryonic stem cells HUES-7,
foreskin-derived mesenchymal stem
cells
0.01, 0.1, 1.0%
(v/v)
RT◦ – Dose-dependent changes in cell viability, morphology, adhesion and gene
expression: inhibition of embryoid bodies formation, decrease in adhesion,
cell death
– Low and medium DMSO doses upregulate mesodermal markers
– Higher DMSO doses downregulate ectodermal differentiation
[11]
Human umbilical cord blood stem
cells
40%, 10% and
DMSO removal
RT◦ and post
thaw
– 40% DMSO lethal. 10% DMSO no viability reduction after 1 h. DMSO
washout improved viability
Optimum 7.5–10%
[12]
Immune cells
Undifferentiated pre-B and pre-T
(RPMI-8402) lymphoid cells
1.5% (v/v)
24–72 h†
– B-cells are resistant to DMSO
– Increased membrane fluidity, cytosolic Ca2+, NOS activity
– Reversible G1 growth arrest of T cells, increased apoptosis, changes in TdT
expression
– Alterations in CD external antigens, TdT, TCR, RAG-1 expression, involved in
growth arrest, decrease in c-myc expression, ODC activity and intracellular
polyamine content, inappropriate differentiation leading to apoptosis
triggering
[13–16]
Neural cells
Retinal neuronal cell line 1, 2, 4, 8% (v/v) – Caspase-3 independent death of neurons
– Inhibition of mitochondrial respiration, increase of cytosolic Ca2+,
phosphatidylserine externalization, translocation of apoptosis-inducing
factor (AIF) from mitochondria to the nucleus, PARP activation, DNA
fragmentation
[17]
Rat hippocampal cells 0.5, 1% (v/v) Neurodegeneration, apoptosis [18]
Astrocytes 1–5%
24 h†
– Decreased survival and viability of astrocytes (1% DMSO)
– Mitochondria swelling. Decrease in mitochondrial membrane potential.
Cytochrome C release from mitochondria. Increased ROS formation
– Apoptosis. Increased caspase-3 expression, decreased anti-apoptotic
protein Bcl-2 and procaspase-3 expression
[19]
Hepatic cells
Rat primary hepatocytes 1% – Prolonged pre-apoptotic phase in hepatocytes due to 24-h post-isolation
DMSO treatment. Redistribution of caspase-9 from the nucleus to cytosol
– Delayed apoptosis triggering
[20]
Blood cells
PBMC;
MM6, RAW 264.7
0.25, 0.5, 1, 2,
4%
37◦C – DMSO concentration of 4% suppresses ROS and IL-6 production in all cell
types (leukocytes and RAW 264.7 are the most sensitive). 0.25 and 0.5%
DMSO stimulate ROS and IL-6 formation in MM6
[21]
Red blood cells 0.2, 0.4, 0.6%
0–72 h†
37◦C – Increased hemolysis at 0.2% DMSO after 6 h and at 0.4% after 0 h [22]
Platelets 0.25–6% CryoT◦ – Inhibition of aggregation, decreased thrombin generation [22]
EAhy926 cells‡ 0.2, 0.4, 0.6%
0–72 h†
37◦C – Decreased proliferation, growth arrest at G1 phase, increased apoptosis [22]
Cancer cells
Monocytes and T leukemic cells 0.1, 0.2, 0.5, 1, 2,
5%
37◦C – Time- and concentration-dependent DMSO cytotoxicity. DMSO
concentrations ≥2% cause decreased proliferation after 24-h incubation
[23]
Promyelocytic leukemic HL-60 cells 1.25%
6 d†
– Inhibited proliferation at the day 2 DNA degradation
– Chromatin condensation and nuclear fragmentation
– Apoptosis in terminal differentiated HL-60
[24]
HL-60 cells 0.25–1% 37◦C – Stimulation of ROS production [21]
HeLa cells 0.1–15% (v/v)
72 h†
37◦C – Decrease in cell number, growth suppression, alteration of cell shape [25]
Colon adenocarcinoma tumor cells
Caco 2/TC7
2–100% 37◦C – LDH release from cells at DMSO concentration 10% [26]
Human embryonal carcinoma NEC-8
and NEC-14 lines
0.2–1% – Increased DNA methylation, aberrant differentiation, downregulation of
stemness markers and resistance to cisplatin
[27]
† Incubation time.
‡Hybridoma cell lines from umbilical vascular endothelial cells and lung cancer cells exhibiting properties of vascular endothelial cells.
MM6: Mono Mac 6; PBMC: Peripheral blood mononuclear cells; ROS: Reactive oxygen species.
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Direct in vivo inoculation of DMSO into rat pups has been shown to elicit significant dose-dependent neurotoxic
effects evidenced by increased levels of apoptosis in neural cells, the severity of which was age related [17,18]. The
toxicity of DMSO for T cells and monocytes seems to be responsible for the observed anti-inflammatory and
anti-oxidant effects of DMSO [23] and this has been confirmed from other data showing the key role of DMSO to
be reduction of IL-6 and reactive oxygen species (ROS) in leucocytes [21], rather than free radical scavenging. While
levels of DMSO in the order of 0.1% v/v are capable of suppressing cell growth, short incubation periods are not
believed to incur permanent significant effects [25]. In clinical use, exposure of hematopoietic stem cells (HSC) to
DMSO at a level of 5–10% v/v for 1–2 h has been shown not to be toxic [41,42]. Reduction of DMSO to 5% has
been reported to achieve improved engraftment recovery times for leucocytes, neutrophils and platelets [43], while
in hematopoietic stem cell preparations this level of DMSO compared with 10% also promotes colony-forming
capacity [44], reduces side effects in patients, promotes levels of CD34+ cells and reduces cell death [45,46].
On exposure to DMSO a range of effects are observed, in a variety of cell types, specifically on the plasma
membrane including changes in membrane fluidity in RPMI-8402 cells [13], induction of membrane dysfunction
in colon tumor cells [26], leading to loss of lipid asymmetry and flipping of phosphatidylserine in retinal neuronal
cells [13,17]. In colon cancer cells, DMSO at the concentration of 0.1% (v/v) can change secondary structure of
proteins, decrease cholesteryl esters in membrane lipids and affect their oxidation status [47]. These membrane
effects impact on important transport systems, resulting in changes of cytosolic Ca2+ levels [13,17] and translocation
of specific messengers involved in mRNA transcription and cell differentiation [48]. Ultimate consequences of
these effects are arrested cell growth and programmed cell death. However, the biological effects of DMSO
are not limited to the plasma membrane and under specific conditions, can include induction of changes in
cytoskeleton [11], oocyte microfilaments [49] microtubules [50] and chromatin changes [13,47] as well as induction of
cellular differentiation [47,51].
The capacity of DMSO to elicit a wide range of effects on cell biology may point to potential concerns around
its use in clinical practice. Numerous cell types have shown adverse biological impact of exposure to DMSO
(Table 1). For example, a range of blood-borne cell types have shown increased expression of IL-6 and ROS
at levels of DMSO, as low as 0.2% (v/v) [21]. Studies on early lineage B- and T-cells have proven to be more
sensitive to DMSO (1.0% v/v for 24–72 h) showing increased apoptosis, reversible growth arrest and inappropriate
differentiation. Adverse impact of DMSO on functionality of nominally nonleucocyte blood components have
also been reported such as increased hemolysis of erythrocytes, inhibited disaggregation and decreased thrombin in
platelets [22] at similarly low levels of DMSO (0.2% v/v). Human stem cells (human embryonic and tissue-specific
stem cells [52] otherwise known as mesenchymal stem [or stromal] cells [MSCs)] show dose dependent (0.1–1.0%
v/v DMSO) effects of DMSO at room temperature on viability, morphology, adhesion and differentiation [48].
Alteration in apoptotic responses has also been reported in rat primary hepatocytes [20] while in a range of neural
cell types, exposure to DMSO (at 0.5–8.0% v/v) can either promote or decrease apoptosis [17–19]. Even potentially
more robust cancer cell lines have shown a range of effects on ROS levels [21], growth rate and cell viability [22–26]
or aberrant differentiation [27]. Microorganisms are also not immune to the effects of DMSO which is reported to
influence expression of a range of genes relevant to cell metabolism and all cell integrity [10].
It should be noted that some of the effects of DMSO, other than for cryoprotection, have been put to good use
in cell cultures. For example, DMSO has been commonly used as an inducer of cellular differentiation probably
associated with its ability to cause chromatin condensation [13] and alter gene expression [48,51,53,54]. This property
has been employed for in vitro assays to provide a mature cellular phenotype [51,54] and to establish continuous cell
lines with irreversibly different characteristics [51].
The DMSO effects described above were observed in noncryopreserved cells. Similar results were obtained for
cryopreserved fetal liver cells (reduction in stemness genesNANOG, OCT4 and SOX2 expression) [55], bone marrow
cells (structural and functional changes in cells) [56].
Secondary cryoprotective agents reducing DMSO
One way to mitigate potential or perceived problems of toxicity when using DMSO in cryopreservation is to
supplement the cryoprotective agents (CPA) mixture with other agents which themselves have cryoprotectant
effects (all-be-it at often lower efficiency than DMSO itself ), but which provide an opportunity to reduce the
overall DMSO concentration. Cryobiologists have experimented with such mixtures for more than 40 years [57],
and while combinations with other CPAs such as glycerol and polypropylene glycol have been used, their addition
to DMSO has been addressed here and in particular in Section 3. Oligosaccharides used in association with DMSO.
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Among a wide variety of molecules with cryoprotective properties, naturally occurring sugars merit special
attention. Their addition to CPA formulations is intended to increase cell dehydration and lessen the required
concentration and time of exposure to DMSO. Application of monosaccharides in cryopreservation is less common
than disaccharides, due to the possibility of nonenzymatic glycosylation of cell proteins and lipids thatmay alter their
functions. Nevertheless, numerous studies have reported the efficiency of glucose containing methanol solutions
for cryopreservation of sperm [38,39].
Disaccharides, in contrast, are widely used as nonpermeating CPA supplements for freeze drying, vitrification
and slow freezing of various cell types [40]. Nonreducing disaccharides, particularly trehalose and sucrose, are known
to have higher glass transition temperatures compared with DMSO, ethylene glycol and 1,2-propandiol [58]. This
property ensures the formation of a uniform glass structure with high viscosity and low motility, thus, restricting
molecular interactions and lowering the cell damage during rapid freezing [59].
At slow cooling rates, the main causes of cell injury are prolonged exposure to hypertonic environment and
the growth of extracellular ice crystals. Inclusion of disaccharides into the CPA composition, on the one hand,
can significantly influence the morphology, shape and size of ice crystals, which, in turn, affects cell survival [60].
On the other hand, hydroxyl groups of disaccharides can interact with the hydrophilic part of proteins and lipid
head groups, thus stabilizing membranes and preventing their damage upon dehydration [61,62]. Recently, it has
been shown that trehalose does not directly interact with proteins but instead played a role in compaction and
stabilization of molecules by decreasing their hydration [63,64]. However, the exact mechanism for improvement of
post-thaw cell survival in the presence of sugars in CPAs remains uncertain.
Since there are no specific transporters for disaccharides in mammalian cells, when added into CPA they tend to
remain in the extracellular space. In this case, their cryoprotective action is insufficient to ensure the preservation of
structural and functional integrity of cells. Meanwhile, application of disaccharides with permeating cryoprotectant
such as DMSO, even in low concentrations, can significantly improve the cryopreservation outcome.
Combination of 0.2 M trehalose and 0.5 M DMSO has been shown to be effective for long-term storage of
adipose aspirates [65]. Cells isolated from lipo-aspirates immediately after thawing had slightly retained growth rate
compared with fresh ones, however, this difference lessened during the following cell culture. Comparable results
were obtained using 6% trehalose, 4% DMSO and 90% fetal bovine serum (FBS) for cryopreservation of adipose
tissue-derivedMSCs (tissue-specific progenitor cells [52]) [66]. MSCs frozen for 6 and 12months showed the viability
of 80 and 70%, correspondingly. After being thawed and plated, cells started to proliferate and were capable of
differentiation into adipogenic and endothelial lineages.
Solutions with trehalose and a reduced concentration of DMSO have been successfully used for cryopreservation
of hematopoietic stem cells [67,68]. Samples cryopreserved with 2.5% DMSO without disaccharide showed a
significant reduction in viability and clonogenic potential compared with those cryopreserved with trehalose or
with 10% DMSO (control group). Application of another nonreducing disaccharide, sucrose, as a cryoprotectant
for hematopoietic stem cells of umbilical cord blood and fetal liver was also effective [67,69]. For instance, the
inclusion of 0.3 M sucrose as an additive to the CPA containing 5% DMSO resulted in a significant reduction of
human fetal liver cell loss during cryopreservation, increased metabolic activity and function (the number of the
myeloid-macrophage colonies). The recovery rate of cells cryopreserved under protection of 5%DMSO and 0.3 M
sucrose mixture was 20% higher than without sugar and did not significantly differ from 10% DMSO alone [69].
However, the efficiency of sucrose to reduce DMSO concentration seems to be lower than that of trehalose. Sucrose
inclusion into CPA allowed reduction of the DMSO concentration to only 5% while for trehalose similar viability
results were obtained with 2.5% DMSO [67]. Experiments carried out by the group of Mantri et al. [70]. have shown
comparable data: CPA containing 0.2 M trehalose with 2% DMSO was superior that the one with sucrose and
DMSO in the same concentrations based on post-thaw viability results and assessment of hematopoietic colony
formation.
Saccharides have been proven to be excellent candidates for cryopreservation of hepatocytes. Yang et al. [71]
tested three sugars (glucose, sucrose and trehalose) and three sugar alcohols (xylitol, maltol and sorbitol) for
improvement of the metabolic function of human hepatocytes that were cryopreserved using DMSO reduced
to 5% concentration. Cell viability, post-thaw attachment rate and metabolic activity (albumin, glucose, urea
metabolism) of cryopreserved hepatocytes were enhanced by the addition of 0.4 M sorbitol into 5% DMSO
solution. The authors concluded that the mixture of 5% DMSO and 0.4 M sorbitol can replace 10% DMSO
in CPA for cryopreservation of human hepatocytes. Recent data obtained by Cardoso, et al. [72] have indicated
the positive effect of saccharides (sucrose, glucose and trehalose) on hepatocytes post-thaw viability when they
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were used in combination with 5% DMSO. Among the different tested sugars, trehalose showed the best overall
outcome.
To increase cell viability after cryopreservation under the protection of saccharides and low nontoxic DMSO
concentrations, CPA can be additionally supplemented with antioxidants such as, catalase, superoxide dismutase,
glutathione, vitamin C and vitamin E. This approach has been tested on human HSCs and amniotic fluid-derived
stem cells. It was demonstrated that a solution containing 60 mmol/l trehalose, 2.5% DMSO, and 100 μg/ml
catalase produced results similar to those for 10%DMSO in terms of survival, proliferation, and expression of stem
cell markers in cryopreserved amniotic fluid-derived stem cells [73].
Reduction of DMSO concentration to a nontoxic level might be reached not only by addition of saccharides into
CPA but is also feasible by preliminary cell loading with sugars. In this case, saccharides can ensure cell preservation
during freezing acting as permeating cryoprotectants.
In order to achieve loading of relatively large sugar molecules into cells, several approaches have been proposed.
Earlier techniques usingmicroinjection and electroporation were associated with increased risk of cell damage [74,75].
In the case of electroporation, the observed cell damage can be mitigated by optimizing the electric field charac-
teristics as shown by Dovgan et al. [76]. In that instance, human adipose tissue-derived cells loaded with trehalose
by reversible electroporation had high survival rates and maintained their functional characteristic after freezing.
Recently, proposed methods for saccharide loading are mainly based on the use of genetic engineering to create
modified cell membrane pores or to insert disaccharide biosynthetic genes into the cell genome, which can be time
consuming and require additional manipulations [77,78].
An alternative protocol for sugar loading in which a critical step is cell culture in the presence of disaccharide prior
to cryopreservation, was shown by Oliver et al. [79]. Their data demonstrated that MSCs were capable to upload
trehalose from extracellular space by a clathrin-dependent fluid phase endocytotic mechanism. The same approach
has been utilized for DMSO-free cryopreservation of endothelial cells and it allowed to achieve high post-thaw cell
metabolic activity [80]. This protocol was considered to be potentially applicable not only for trehalose but for other
disaccharides as well.
Recently, it has been confirmed that inclusion of mannitol, lactose, sucrose, trehalose and raffinose into the
culture medium for 24 h prior to freezing resulted in a significant increase of human dermal MSCs (tissue-specific
progenitor cells) survival [81]. The authors claimed that optimal concentration of disaccharides in extracellular space
for cell pretreatment (loading phase) was 0.2 M. Nonetheless, culture of human adipose tissue-derived MSCs in the
presence of sucrose in the same concentration led to cell lysis by osmotic shock [82]. Positive results were achieved
when using a solution containing 0.1 M of sucrose. These observations point to the need for screening of optimal
sugar concentration and exposure time for each specific cell type.
In conclusion, the cryoprotective effect of saccharides in a wide variety of biological systems has been confirmed
in numerous studies and when combined with relatively low concentrations of DMSO, they are capable to preserve
both structure and function of frozen cells.
Supplementation of DMSO with high molecular weight macromolecules
Mixtures of DMSO with high molecular weight macromolecules may have some advantages over solutions con-
taining DMSO alone. During a relatively short time of equilibration required for penetration of DMSO into a
cell, high molecular weight agents do not penetrate and act by extracellular mechanisms. The cryoprotection of
cells is elicited by their ability to absorb water and confine osmotic gradients. As polymers are high molecular
weight macromolecules which lower the freezing point (on the basis of kinetics of cooling), they permit avoidance
of excess supercooling and reduce the cooling rate required for cell survival. These properties combined with high
viscosities at low temperature, prohibit water molecules from forming ice crystals outside the cell during cooling
and suppress recrystallization during thawing [83]. Due to different mechanisms of action of nonpenetrative high
molecular weight agents added together with penetrative DMSO into a cryoprotective solution, there may be an
additive effect resulting in reduction of DMSO concentration required for cell cryoprotection.
Mixtures of high molecular weight macromolecules in combination with DMSO and other penetrative CPAs,
are frequently used for cryopreservation of the most biological objects by vitrification. Here we put attention on
conventional slow freezing cryopreservation as an approach that allows to reveal a potential of individual high
molecular weight macromolecules to enable the use of reduced DMSO concentration and, thus, minimize the toxic
effect of this cryoprotectant.
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Among a wide variety of high molecular weight agents for cryobiological projects, preference should be given to
those that have proven biocompatibility in cell culture practice and/or approved for clinical application. FBS is a
common supplement in culture media which contains proteins, growth factors and hormones and promotes cell
adhesion and proliferation. FBS in concentrations from 10 to 90% in combination with 10% DMSO is usually
included into CPA. Bovine serum albumin (BSA) is a major component of FBS that provides its cryoprotective
efficiency due to stabilization of osmotic pressure and protection of cells during freezing and thawing. Thereby, FBS
can contribute to reduction of DMSO concentration. Thus, Zhao et al. [84] have shown that the use of either 20%
FBS or 70% FBS in combination with 5% DMSO produced similar results to combination with 10% DMSO for
recovery of fetal human liver CD34+ cells after conventional slow freezing cryopreservation.
Due to its xenogeneic origin, the US FDA does not permit the use of FBS in products intended for humans. This
problem can be avoided by using autologous or allogeneic human serum, although obviously this must be screened
for human pathogens. Mitchell et al. [85] compared viability, morphology, growth and capacity to multilineage
differentiation of equine MSCs after cryopreservation with either FBS or autologous or allogeneic serum. It has
been shown that an allogeneic or autologous serum can be used for animal component-free MSC cryopreservation.
Moreover, independently of the source of serum (autologous, allogeneic or xenogeneic) their presence in freezing
media in combination with DMSO reduced to 5% was sufficient to preserve viability and growth of MSCs at the
level of 10% DMSO.
Many disadvantages associated with the use of serum, such as inconstant quality, variation in composition among
serum lots, risk of pathogenic contamination, high cost etc., drive the development of serum-free (cryopreservation
media suitable for clinical-grade cell banking. Though the roles of individual components of serum have not been
fully determined, proteins seem to play a key role in its cryoprotective properties. For replacement of FBS in culture
media, the protein sericin, derived from the silkworm cocoon, was proposed by Terada et al. [86]. It has been reported
that addition of sericin in culture medium promoted cell attachment and proliferation, stimulated the synthesis
of collagen and demonstrated antioxidant and mitogenic activities [87]. Sericin has been successfully used also for
cryopreservation of various cell types [87–89]. Sericin at a concentration of 1% in the freezing medium containing
10% DMSO, may substitute FBS for cryopreservation of human MSCs, but is not effective with reduced DMSO
concentration [90]. On the other hand, the combination of 1% sericin and 7% DMSO in CPA ensured similar
survival rate and function (insulin secretion) of rat pancreatic islets compared with 10% DMSO with FBS [91].
After transplantation, islets cryopreserved with either 10% DMSO or 7% DMSO in combination with 1% sericin
indicated similar results in blood glucose control and renal subcapsular engraftment. Given these results, it seems
that supplementation of CPA with sericin could allow reduction in DMSO concentration.
Among synthetic high molecular weight macromolecules, there are advantageous examples that are able to biode-
grade in vivo after cell transplantation or transfusion, thus avoiding the need to remove them after cryopreservation.
Hydroxyethyl starch (HES) is one such molecule that exhibits colloidal properties similar to human albumin and
is widely used as a plasma substitute in adults for the treatment of shock caused by hemorrhage, burns, sepsis,
ischemia/reperfusion and other injuries [92]. HES is metabolized by amylase and HES fragments are subsequently
eliminated from the circulation after infusion. HES is free of side effects and often has been used in cryopreserva-
tion protocols. Properties of HES as a cryoprotectant have been reviewed by Stolzing et al. [93]. In concentrations
≥10% HES alone has demonstrated highly protective effects for the cryopreservation of keratinocytes [94,95], bone
marrow cells [96], Chinese hamster cells [97], red blood cells of human [98,99], domestic animal origin [100] as well as
other cells. A comparative evaluation of HES and DMSO as cryoprotectants was performed and in two studies,
Ashwood-Smith et al. have shown that HES alone is less effective than DMSO [97,101]. Many more papers have
focused on the admixture of HES with other CPAs including DMSO. Naaldijk et al. [102] have confirmed that HES
alone could not provide sufficient cryoprotection of ratMSCs, but in combination withDMSOwas effective. Using
several cooling protocols, it has been shown that the supplementation of CPA with 5% of HES permitted reduction
of DMSO concentration to 5%, although the highest viability of MSCs after post-thaw recovery in culture was
observed using the mixture of 8% DMSO and 2% HES. It is interesting that the cryopreservation with HES of
different molecular weights in the range from 109 to 609 kDa had a minor effect on survival and differentiation
capacity of MSCs. A more recent study of this team has confirmed the ability of HES to facilitate reduction of
DMSO concentration for adherent skin tissue cells (fibroblasts and keratinocytes) [103]. Cell lines and primary
fibroblasts in suspension and monolayer have been cryopreserved using controlled rate freezing in CPA containing
HES, DMSO and FBS. Testing cell number and viability, maintenance of nuclei, actin and mitochondria markers
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it has been shown that cryopreservation of fibroblasts and keratinocytes both in suspension and in monolayer was
successful using mixture of 5% DMSO, 5% HES and 90% FBS.
Due to a 6% HES of average MW 450,000 Da (Hespan R©) is used for plasma expansion this hetastarch has
been most widely studied in cryopreservation projects for reduction of DMSO toxicity. This is primarily related to
cryopreservation of hematopoietic stem cells (HSCs). Mixing 5% DMSO with HES of MW 450,000 Da showed
better recovery rates of CD45+ and CD34+ cells and colony forming unit (CFU) recovery after cryopreservation
of HSCs derived from cord blood and peripheral blood than DMSO alone [104]. Cryopreservation of human bone
marrow cells by conventional slow rate cooling protocol in CPA containing a combination of 5% DMSO, 6%
HES and 4% human serum albumin, resulted in better survival and CFU recovery of HSCs in culture compared
with 10% DMSO without serum [105]. Similar results have been obtained on canine bone marrow-derived HSCs
cryopreserved using slow rate freezing in CPA containing either 10% DMSO and 90% FBS or 5% DMSO, 6%
HES and 4% BSA [106]. Cryopreservation in the mixture HES, BSA and reduced concentration of DMSO provided
higher post thaw cell viability and CFU recovery rates than 10% DMSO in fetal serum.
CPA containing HES with a lower average of MW (264,000 vs 450,000 Da) (Pentastarch) in combination with
25% human albumin and 5% DMSO has demonstrated high efficiency for cryopreservation of human cord blood
HSCs [107]. A randomized Phase III clinical trial has shown that patients who received autologous peripheral blood
HSCs cryopreserved with the combination of 5% DMSO, 6% HES and 4% human serum albumin, recovered
their white blood cell level more quickly, than those who received peripheral blood (PB)-HSCs cryopreserved with
10% DMSO and 90% human serum [108]. This combination has demonstrated efficiency also on dog islets that
after cryopreservation in CPA containing 6% HES and 4% FBS in composition with reduced to 5% DMSO
maintained a high recovery rate.
In a number of countries, dextran is used clinically in plasma volume expansion, thrombosis prophylaxis and
peripheral blood volume enhancement. Ashwood-Smith et al. [109] found that dextran of molecular weight (MW)
70,000 Da in concentration 9% has provided good protection of CHO cells cryopreserved with cooling rate
approximately 20◦C/min in CPA that contained 10% fetal calf serum. Addition of 1% DMSO to 9% dextran
yielded survival rates as high as those obtained with 10% DMSO. In previous experiments of this group [109]
performed on the same cell type (Chinese hamster cells) and using the same cryopreservation protocol in the
absence of FBS showed no so significant improvement in cryoprotection when using a number of dextrans of
average MW 10,000–500,000 Da. This data was corroborated by another report [110], where addition of 10%
dextran of MW 100,000 Da into CPA without serum failed to improve viability of stem cells derived from human
fetal liver after cryopreservation with DMSO in a range of concentrations from 2 to 10%.
Polyglucinum containing 6% of dextrans of MW 50,000–70,000 Da is also used for reduction of the volume of
human UCB. Makashova et al. [111] have reported that dextrans in the concentration of 3% obtained after mixing
of UCB with polyglucinum in the ratio 1:1 (v/v) is suitable both for collection and cryopreservation of nucleated
cells. Cord blood nucleated cell concentrates containing 3% dextran were supplemented with DMSO in the range
of concentration from 2.5 to 10% and cryopreserved using controlled rate freezing. Post thaw viability of CD45+
cells did not differ in samples cryopreserved with the combination of 5%, 7.5% and 10% DMSO. Although this
study did not compare post-thaw viability after cryopreservation withDMSO alone, the data indirectly demonstrate
ability of dextran to reduce DMSO concentration in cryopreservation of hematopoietic cells.
In biomedical practice including cryobiological projects, synthetic high molecular weight polymers are widely
used. These polymers demonstrate excellent biocompatibility, and are biodurable materials, because cells of an-
imal and human tissues have no correspondent metabolizing enzymes and their biodegradation or resorption
occurs by reticuloendothelial system. Among such agents, polyethylene glycol (PEG), methylcellulose (MC) and
polyvinylpyrrolidone (PVP) are the most commonly used as nonpermeable cryoprotectants.
PEG is a polymer of ethylene glycol readily available in a wide range of molecular weights. It is nontoxic and has
been applied in biomedical research as drug-delivery system, tissue engineering scaffolds, etc. PEG has been also
included in solutions for hypothermic storage of kidney and liver [112,113]. There were several studies describing
cryopreservation of red blood cells [114], pancreatic islets [115,116] and vein grafts with PEG alone [117]. However,
more often it has been used in mixture with permeable CPAs, mostly DMSO to reduce its toxic effect.
Petrenko [110] has studied an influence of PEG of MW 1500, 3500 and 8000 Da in combination with different
(2%, 5%, 10%) concentrations of DMSO on viability of human fetal liver cells after slow-rate cryopreservation. It
has been shown that PEG with different molecular weight increased survival of cells after cryopreservation included
three-step programmable freezing protocol (1◦C/min down to -40◦C, 10◦C/min down to -80◦C and storage in
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liquid nitrogen). Survival rate determined after rapid thawing and washing out of CPAs increased with enhancement
of molecular weight of PEG. The highest values for survival rates were obtained after cryopreservation of human
fetal liver cells in CPA containing 6% PEG of MW 8000 Da in combination with DMSO. Supplementation of
CPA with the PEG provided a high cell viability which enabled reduction of DMSO to 2% concentration.
Yang et al. [118] compared the effects of PEG and trehalose in CPA with a reduced concentration of DMSO on
slow-freezing cryopreservation of bone marrow derived MSCs from mice, rats and calves. It has been shown that
DMSO could be partially replaced by PEG and/or trehalose for MSCs cryopreservation from all three species.
However, the post-thaw viability, metabolic activities, proliferative capacity and differentiation potential varied
among the different species. CPA containing 2% PEG, 3% trehalose and 2% BSA in the combination with reduced
to 5% concentration of DMSO demonstrated satisfactory values of viabilities and metabolic activities. In another
study [119] these authors have shown the ability of PEG to reduce DMSO concentration for cryopreservation of
human bone marrow-derived MSCs. The post-thawing viability of cells cryopreserved in CPA containing 7.5%
DMSO, 2.5% PEG and 2% BSA was comparable with that obtained in conventional cryopreservation in CPA
included 10% DMSO (82.9 ± 4.3% and 82.7 ± 3.7%, respectively). MSCs cryopreserved with reduced DMSO
concentration were able to differentiate toward osteogenic, adipogenic and chondrogenic lineages. Unfortunately,
the molecular weight of PEG in these reports has not been indicated. In the study [119] addition of 5 or 10%
PEG of MW 8000 Da to CPA failed to reduce DMSO concentration in CPA after conventional slow-freezing
cryopreservation of stallion germ cells, but gave better results than DMSO alone. At supplementation of CPA,
containing 10% DMSO, enhanced viability of germ cells from post-pubertal stallions. Similarly, addition of
2.5% PEG with MW 1000 Da to CPA containing 10% DMSO and 10% FBS has significantly improved post-
thaw recovery rate, culture potential and stem cell activity in cryopreservation of mouse testis cells enriched for
spermatogonial stem cells [120]. In the frame of the current review it would be of interest to evaluate the ability of
PEG to reduce DMSO concentration; however, it has not been done in currently available studies.
Methylcellulose (MC) is a macromolecular polymer that has been successfully used as a supplement in a serum-
free cell cultures [121]. In such cultures, it has been shown that MC can replace animal serum in the standard CPA
containing 10% FBS [122,123]. These data demonstrate that MC can be considered as an alternative to FBS in the
cryopreservation of cells for their following clinical use. Thirumala et al. [124] have used methylcellulose either alone
or in combination with reduced levels of DMSO for cryopreservation of short-term expanded (Passage 1) adult
human adipose tissue derived stromal cells. It has been indicated that MC alone did not provide the protection of
stromal cells after conventional slow-freezing cryopreservation protocol. After thawing high levels of necrotic and
apoptotic cells have been observed. At the same time 1% MC produced similar satisfactory results with DMSO
in the concentrations of 2, 4, 6, 8 or 10%. After cryopreservation in CPA containing the combination MC and
reduced as low as 2% concentration of DMSO cells demonstrated high viability, low percentage of apoptotic cells
and maintained their adipogenic and osteogenic potential.
PVP is a water soluble synthetic high molecular weight polymer, which has many desirable properties including
low toxicity, chemical stability and good biocompatibility. Due to these properties, PVP has been used in biomedical
applications such as binders in pharmaceutical tablets, hydrogels for wound dressings, disinfectants and as a blood
plasma substitute. It has been reported that PVP with an average molecular weight of 40,000 can be used as
alternative to permeable CPAs as DMSO for conventional slow-freezing cryopreservation of human adipose tissue-
derived MSCs [125] and isolated rat islets [116]. Comparison of PVP and DMSO at concentrations of 10% after
cryopreservation in CPA supplemented with 10% FBS using controlled rate freezing protocol has been studied on
human Wharton’s jelly-derived MSCs [126]. Although DMSO demonstrated a 20% higher post-thaw cell viability,
after recovery in culture MSCs cryopreserved with both DMSO and PVP the cells maintained their morphological,
immunophenotypic and differentiation characteristics. Poorer cryoprotective efficiency of 10% PVP compared with
10% DMSO has been also shown on human stromal vascular fraction of adipose tissue [127]. The combination of
PVP and DMSO was tested for slow cooling cryopreservation of hepatocytes. Such combinations did not offer any
advantage over DMSO alone for the cryopreservation of rat hepatocytes [128]. Go´mez-Lecho´n et al. [129] reported
that freshly isolated rat and dog hepatocytes, cryopreserved in CPA containing 10%DMSO and 2.3% PVP showed
similar viability but significantly higher recovery (cell attachment to the plates andmonolayer formation) than those
frozen in CPA containing DMSO alone. Hepatocytes cryopreserved in CPA containing DMSO and mixture of
DMSO and PVP similarly maintained their capacity of response to P450 inducers and drug-metabolizing activity.
Thus, although there are no direct literature data that the supplementation of CPA with PVP reduces effective dose
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Table 2. High molecular weight macromolecules able to reduce dimethyl sulfoxide concentration.
Agent Cell type Reduced DMSO
concentration
Additional substitutes Tests (activity, function) Ref.
FBS 95% Equine MSCs 5% No Viability, morphology, growth and
capacity to multilineage differentiation
[85]
FBS 20%, 70% Human fetal liver HSPCs 5% No Viability, CFU recovery [84]
Sericin 1% Rat pancreatic islets 7% 0.1 M trehalose Survival, insulin secretion, blood glucose
control and renal subcapsular
engraftment
[91]
2–5% HES Rat MSCs 5-8% No Viability, differentiation capacity [102]
5% HES Fibroblasts and
keratinocytes
5% 90% FBS Viability, maintenance of nuclei, actin
and mitochondria markers
[103,132]
6% HES Human BM-HSCs 5% 4% BSA Survival, CFU recovery [105]
6% HES Canine-HSCs 5% 4% BSA Survival, CFU recovery [106]
6% HES (Pentastarch) Human UCB-HSCs 5% 25% human albumin Survival, CFU recovery, engraftment in
SCID mice
[107]
6% HES Human PB-HSCs 5% 4% human serum albumin Viability of CD34+ cells, engraftment [108]
9% dextran (MW 70 kDa) Chinese hamster ovary
cells
1% 10% fetal calf serum Survival [109]
3% dextran (MW 50–70
kDa)
Human UCB nucleated
cells
5% No Viability of CD45+ cells [111]
6% PEG (MW 8000 Da) Human fetal liver HSPCs 2% No Survival rates [110]
2% PEG (MW – NI) Mice, rats and calves
BM-MSCs
5% 3% trehalose and 2% BSA Viability, proliferation and
differentiation
[118]
2.5% PEG (MW – NI) Human BM-MSCs 7.5% 2% BSA Viability, differentiation [119]
1% MC Human AT-MSCs 2% No Viability, differentiation [127]
BSA: Bovine serum albumin; CFU: Colony forming unit; FBS: Fetal bovine serum; HES: Hydroxyethyl starch; HSC: Hematopoietic stem cell; HSPC: Hematopoietic stem cell; MSC: Mes-
enchymal stem cell; UCB: Umbilical cord blood.
of DMSO, the mixture of PVP and DMSO manifests additive or synergistic enhancement of cell viability and
function after cryopreservation.
As nonpermeable high molecular weight cryoprotectants special mention should be given to polyampholytes.
Matsumura et al. [130,131] have reported that carboxylated poly-l-lysine of MW about 5000 Da at a concentration
of 7.5% without any additional substitutes was as efficient for cryopreservation of multiple cell types as 10%
of DMSO. The authors assume that cryoprotective mechanism of carboxylated poly-l-lysine differs from high
molecular weight polymers and caused by membrane protection similar to antifreeze proteins.
Studies where supplementation of CPA with high molecular weight molecules resulted in reduction of DMSO
concentration are summarized in the Table 2. Unfortunately, it is difficult to compare ability of different macro-
molecules to reduce DMSO concentration, because they were done on different cell types using different cry-
opreservation protocols. In many studies, additional substances such as trehalose, albumin or serum have also
been used. The effect of the individual substances is difficult to assess. Anyway, these studies demonstrate that
cryopreservation of different cell types using a mixture of DMSO and high molecular weight agents allows the
reduction DMSO concentration resulted in avoiding it toxicity with simultaneous improvement of cell viability.
Removing DMSO from the cryopreserved cell-based grafts & preparations
In this section, we will discuss the current technologies for the removal of DMSOusing the example of cryopreserved
grafts, with the specific focus on clinical practices.
The common strategy of DMSO removal includes the gradual step-wise dilution of the cryoprotective agent-
containing cell suspension with washing solution, at a rate that ensures the maintenance of cells within their osmotic
tolerance limits, and thus, avoiding the extensive cell swelling [133,134]. For this approach, several parameters should
be considered and adjusted in each specific case. The volume of the sample, concentration and osmolarity of the
CPA solution applied during cryopreservation, the temperature of the cell preparation and finally the cell type are
the most critical factors occurring during CPA removal. Considering these factors, it is possible to generate an
optimized protocol for CPA removal by combining the washing solution(s) composition, addition/equilibration
rate and the number of dilution steps needed to reach the best result. The composition of washing solution
10.2217/rme-2019-0145 Regen. Med. (Epub ahead of print) future science group
DMSO: efficacy balanced by toxicity? Review
would partly determine the overall rate of CPA removal. The larger the difference between osmolarities of washing
and CPA solution, the slower the dilution rate used to maintain cells within osmotic tolerance limits. The
supplementation of the washing solution with nonpermeable compounds (usually sugars) in quantities almost
reaching the concentration of permeable CPA can moderate the influx of water into the cells and control the
overall osmotic cell swelling [134]. After the washing medium is added, the cells are concentrated by centrifugation
to remove the remaining CPA from the thawed sample, although that in turn, results in the additional stresses
and damaging factors, associated with physical forces applied on the sensitized cells. Therefore, the development
of the ideal protocol of CPA removal is challenging and requires good scientific understanding of many variables.
Using mathematical modeling or computer simulation, significant efforts have been made to predict the outcomes
and propose the best CPA addition/removal protocols for the specific applications [12,135,136]. However, our lack of
ability to develop a unified protocol, due to the diversities in cellular characteristics, as well as the absence of easy
to reach information sources (such as pre-adjusted software or open access on-line resources) to provide nonexpert
researcher with the best options for the specific cell type, slow down the implementation of simulated data into
routine cryopreservation practice.
The removal of DMSO in current clinical cryopreservation methods and banking of cell-based grafts is even
more challenging, since additional highly regulated factors are introduced into the processing pipeline, but these are
important to ensure patient safety and reproducibly effective application of the procedure. These issues have triggered
the following multidisciplinary studies aimed to provide efficient options, combining cell biology/cryobiology and
engineering approaches.
Removal of DMSO from cryopreserved hematopoietic stem cell grafts
The high clinical demand for hematopoietic stem cell transplants has driven the research toward the development
of safe and efficient cryopreservation and cryobanking protocols for HSC grafts. In the majority of cases, the
cryopreservation of HSC for clinical application is made under protection of 10% DMSO [36,137] that brings the
problem of DMSO toxicity and optimization of the DMSO removal process to the forefront as a key issue to be
resolved for sample processing.
Going back to the common steps of DMSO removal process, briefly discussed before, it is necessary to highlight
at least several factors, which are critical in the case of clinical HSC processing.
1. Volume – typically a range of 25–100 ml of cryopreserved HSC graft is prepared in sealed cryogenic bags that
require optimized protocols for DMSO removal. On the one hand, the rate of the dilution should be controlled
to maintain the osmolarity of the total solution within the osmotic tolerance limits of processed cells, but on
the other hand, it has to be fast enough to avoid the prolonged exposure of cells to the toxic DMSO.
2. Washing solution – research processes for DMSO removal, give the researcher wide flexibility in choosing the
washing media components, however, the processing of cells for clinical use is more rigorous and consequently
the choice is usually limited by the availability of suitable products that are currently registered pharmacopeia
products permitted for direct infusion into a patient.
3. Closed environment – since theDMSO removal is considered as an additional openmanipulation, the procedure
of washing should be done either in the laboratory (i.e., clean room facilities suitable for GMP manufacturing)
or prepared in closed systems, preserving sterility and thus, high safety of cell-based preparations.
4. Reproducibility and automation can be considered as a fourth major task in clinical DMSO removal.
Manual methods of DMSO removal based on dilution/centrifugation approach
The current standard methods for the DMSO removal from the cryopreserved HSC are based on the protocol
proposed in 1995 by Rubinstein and colleagues from the New York Blood Center [138]. With or without small
modifications, this method comprises two-step dilution of each stem cell unit (donor cell preparation with washing
solution followed by centrifugation [133,139]. The precise step-by-step procedures of the current clinical-standard
DMSO washing from HSC grafts are freely available from the FDA-approved product database (www.fda.gov).
DMSO removal by washout methods has also been shown to improve viable recovery of cord blood cells [140].
Analyzing the information from different UCB banks, the common procedure of DMSO removal contains several
steps, each at 4−10◦C shown below:
• preparation of washing solutions in Luer-Lok syringes or washing bags;
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• establishment of the closed system by connecting several bags/syringes by tubing and Luer-Lok connectors and
clamps;
• unsealing and connecting the unit to the established closed system;
• first-step dilution of the unit with washing solution (5–25 ml) and transferring the unit into
transfer/washing/transplant bag, using the established tubing;
• second-step dilution of the unit with larger volume of the washing solution;
• centrifugation at 400–880 ×g for 10–20 min at 4◦C;
• adjustment of the transplant volume using the washing solution or supernatant.
The compositions of the washing solution may vary in different institutions, but generally is limited to the
mixtures of saline/electrolyte media (0.9% NaCl, Lactated Ringer’s, Normosol-R R©, Plasma-Lyte 148 R© or similar)
with dextran-40 (5–10%), human serum albumin (1–5%) or HES (3–6%), Tetraspan R© Volulyte R©) or acid citrate
dextrose anticoagulant [141–146].
Although the described procedure is considered as the standard, it is a very time- and labor-consuming process,
which needs the involvement of trained personnel and special facilities assuring sterility of the graft. Moreover, the
dilution process of the DMSO-containing grafts is not well controlled, since it is manual and affected by human
factors and can result in lack of reproducibility. This drives the need of the development of automatic devices,
providing a controlled, reproducible environment during the washing procedure.
Device assisted methods for DMSO removal based on dilution/centrifugation approach
Several devices have been proposed for automation of the centrifugation-based removal of cryoprotectant from
cryopreserved hematopoietic grafts. The COBE R© 2991 Cell Processor (Terumo BCT, Inc.) represents one of the
solutions for fast automatic processing of blood or bone marrow units [139,142]. The key feature of the COBE 2991
cell processor is the presence of a flexible diaphragm. When the centrifuge is spinning, the flexible diaphragm
located inside the centrifuge bowl, can be inflated with hydraulic fluid. As the flexible diaphragm inflates, it presses
against the bottom of the cell processing bag. This gives the COBE 2991 cell processor the ability to express fluids
and/or cells for removal or collection during centrifugation. Sepax S-100 R© (or Sepax 2 S-100), available from
Biosafe SA R©, GE Healthcare represents another option of automatic processing of hematopoietic grafts, including
umbilical and peripheral blood or bone marrow [143,144]. The technology relies on the use of a separation chamber
that provides both separation through rotation of the syringe chamber (centrifugation) and component transfer
through displacement of the syringe piston. In both cases, manufacturers provide the possibility to prepare the
washing procedure in a closed environment, significantly reducing the risks of contamination. Abonnenc et al.,
showed that the Sepax-2 assisted washing of autologous HSC grafts resulted in 95% removal of DMSO (used as
10%) and post-wash viable CD34+ cell recovery of around 80% [147].
Device-assisted methods of DMSO removal based on dilution/filtration approach
Another technologically different approach for CPA removal from the cryopreserved grafts is based on the
filtration/dilution technique. The pioneering automation using this approach is based on the development of
the spinning bowl for deglycerolizing of red blood cells, where cells initially sediment to the periphery of the bowl
and the diluting solution is slowly introduced at the periphery [133,148]. Further progress in utilizing this technique
resulted in the development of Haemonetics ACP215 Automated Cell Processor R© (Haemonetics Corporation).
However, this device is mainly employed for glycerolization and deglycerolization of red blood cell units and little
is known about the use of this device for DMSO removal. Starting from the early 2000s several reports have been
presented on the use of CytoMate R© (Baxter/Nexell) closed fluid management system for automatic washing of
hematopoietic transplants. Calmels et al. showed that the removal of DMSO from cryopreserved HSC grafts was
associated with limited loss of CD34+ cells, while 96% of DMSO was eliminated [149]. The successful application
of this device was also confirmed for umbilical cord blood units [150] and peripheral blood products [151,152]. The
authors showed that the degree of removal of DMSO is very high and therefore might ameliorate the transfusion-
related side effects of cryopreserved HSC transplants. Recently, the new Lovo R© filtration-based device has been
launched by Fresenius Kabi for automatic washing and volume reduction of white blood cells [153]. Authors indicate
that the Lovo device is an advantageous option for efficient washing and enriching of more than one thawed HSC
graft simultaneously. The two- or three-cycle washing resulted in 96–98% elimination of DMSO and around 80%
viable CD34+ cell recovery from the cryopreserved peripheral blood HSC grafts [153].
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Although, the presented automation solutions can significantly improve the reproducibility of processing of
clinical HSC grafts, the high cost of these devices determines their adoption by large transfusion centers with high
numbers of routine clinical applications of HSC transplantations. Adaptation of a hollow fiber dialysis approach
for CPA removal can represent an alternative cost-efficient option for the controlled and safe washing of DMSO
from cryopreserved tissue products [154,155], however, the more wide-spread use of this method is limited by the
large volumes of the processed samples and requires adaptation for smaller size tissue products.
Removal of DMSO from small volume cell-based & tissue-engineered grafts
In the previous sections, we have reviewed the possibilities of clinical-grade DMSO removal from large-volume
HSC grafts. However, currently the field of regenerative medicine has stepped far beyond HSC transplantation
toward the development of effective treatments for nonhematopoietic disorders, specifying so-called multipotent
MSCs as the most frequently applied cell type [155]. The accurate nomenclature and biological identity of these cell
preparations is the subject of current debate and any differences within this cell type in response to DMSO is not
yet clear [52,156,157].
The common practice of nonsystemic local administration of MSCs includes the application of more than
0.5 × 106 cells per kg of bodyweight in a limited volume of vehicle solution. In this case, the final administration
dose can comprise up to 108 cells in only a few milliliters of the solution (<10 ml). Cryopreservation may
represent the only choice to provide fast availability of cellular graft for application as well as assure the safety and
quality of the product in repeatable application. However, the presence of high concentrations of DMSO in the
vehicle solution may negatively act locally on the patient’s cells and tissue within the site of injection as discussed
above. For example, Galvao et al. showed that the DMSO induces retinal apoptosis in vivo at low concentrations
(>1%) [17]. In an in vitro rat hippocampal culture preparation, DMSO produced neuronal loss at concentrations
of 0.5 and 1.0% [18] and other reports are explained in Section 1. These reports confirm the need for reducing
DMSO concentration in cryoprotective medium, especially when the cellular product is supposed to be used
for the restoration of neural tissue. Moreover, safety guidance remains similar to large volume grafts (e.g., HSC
transplants). Thus, the development of controllable engineering approaches of DMSO removal from the small
volume cryopreserved grafts seems highly desirable to achieve the necessary therapeutic outcomes and minimize
vehicle solution-associated side effects.
Recently, Tostoes et al. demonstrated the use of a novel filtration system for the removal of DMSO from
cryopreserved small volume samples, containing 107 fetal lung fibroblasts or bone marrow MSCs [158]. The system
resulted in the elimination of 85–95% of DMSO with more than 70% cell recovery. Memon et al. introduced
the device for controllable extraction of DMSO from the frozen-thawed samples, based on sandwich structure,
composed of two channels, separated by polytetrafluoroethylene (PTFE) membrane and syringe pumps [159].
Microfluidic devices have emerged as a promising technology for manipulating cell populations in small scaled
microchannel systems [160]. The removal of CPA in such devices is achieved mainly through diffusion, reducing
osmotic stresses and thus, damaging factors, which may occur in cells subjected to other techniques [161]. Moreover,
microfluidics systems provide the user with highest degree of process control and reproducibility, which are
important aspects of clinical processing of cell-based grafts. Park et al. applied an electro-wetting-on-dielectric-
based microfluidic platform to screen DMSO mixtures on cell toxicity and cryoprotection efficiency [162]. Song
et al. applied a microfluidic device to control loading and unloading of CPA by diffusion and laminar flow [160].
The group of Hubel also studied in some depth, the possibilities of using microfluidic devices based on diffusion-
based extraction of DMSO from cell suspensions [161,163,164]. Starting from a two-channel flow system, where the
DMSO-containing cell suspension is simultaneously flowing in parallel with the washing solution [163], the process
has been optimized by introducing either several stage devices [164] or three-channel systems [161]. As a result, more
than 95% of DMSO extraction can be achieved, while preserving the viability of cells. Authors assumed, that the
transport of CPA from the cell-laden stream to the wash streams occurs solely by cross-stream diffusion, driven by
the concentration gradient [161].
The administration of stem cells within biomaterial scaffolds may provide several advantages over the classical
cell therapy in particular applications. 3D organization, more physiological elastic properties and cell–cell, cell–
matrix interactions provide additional cell support and enhance the survival and therapeutic properties of stem
cells in localized delivery. To provide wide availability of tissue-engineered grafts for further applications, efficient
cryopreservation protocols are needed, including the efficient loading of CPA into 3D construct, finding the optimal
freezing and thawing protocols and finally washing off the CPA from the thawed sample. In this case unusually, the
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cell–cell and cell–matrix interactions may negatively affect cell viability and function after cryopreservation [165–167].
It has been shown that cells attached to gelatin- and Matrigel-based substrates can largely survive cryopreservation,
although the cell viability of adherentMSCs is significantly lower (up to 35%) than that in suspension [165,166]. There
are several reports on the cryopreservation of 3D tissue-engineered grafts, employingDMSOas a cryoprotectant [167–
172]. However, the analysis of the functional properties of cryopreserved grafts has been currently limited to the in
vitro studies. TheDMSOunloading is usually prepared in static conditions (diffusion), by continuous changes of the
CPA with washing solution (usually culture medium) [168,170]. In turn, the clinical cryobanking of tissue-engineered
grafts would likely bring similar challenges, presented for cell-based transplants and thus, the development of reliable,
automation devices, assuring reproducible cryopreservation outcomes and avoiding the possible toxicity associated
withDMSO residues is an important aspect. Recently, several reports have shown the application of bioreactor-based
devices for cryopreservation of MSCs within 3D scaffolds [167,169]. The application of oscillating perfusion systems
for the controlled loading and unloading of DMSO resulted in a significant increase in MSC recovery within
collagen scaffolds [169]. Applying a microfluidic bioreactor system Bissoyi et al. concluded that MSCs attached
to a particular substrate can be effectively cryopreserved, if subjected to lower shear stress [167]. Altogether, the
precise control over the environment could assist in the establishment of standardized cryopreservation protocols
for complex tissue-engineered grafts for clinical applications.
Concluding remarks on post-thaw DMSO dilution to reduce negative effects
Much effort has been made toward the development of safe and reproducible systems and protocols of DMSO
removal from the cryopreserved grafts in clinical scale, especially in the field of HSC transplantation. However,
it remains the case, that DMSO elimination is not provided in the majority of HSC transplants [137] associated
with negative effects. Therefore, the development of low-cost, automatic devices to remove DMSO, assuring
minimal contamination probability and high control and reproducibility of the process may be considered critical
in translating stem cell/tissue engineering research into a wider range of clinical practice.
Alternatives to DMSO
In recent years, the concept that it will be possible to replace DMSO in cryopreservation media while still
maintaining good post-thaw recoveries has been discussed [173]. However, a wide application for such an approach
has yet to be achieved. This section gives an objective assessment of the current status for this approach.
Theoretical alternatives based on equivalent mechanism of action
In the following, we discuss the potential substitution of the specific mechanisms that have been attributed to
DMSO in generating a cryoprotective effect.
Perhaps themost significant aspect ofDMSO-related cryoprotectant activity is linked to its capability to enter cells
easily both through osmosis and potentially via aquaporin 3-independent channel diffusion [174]. One consequence
of this is intracellular water displacement, which is a putative cryoprotective mechanism limiting intracellular
ice crystal formation. Water displacement with limited osmotic stresses is also associated with other ‘penetrating’
cryoprotectants such as sugar alcohols (e.g., ethylene glycol, propylene glycol, glycerol) and other compounds.
Although findings differ significantly for different cell types, in general terms, DMSO seems to exhibit the lowest
membrane permeability coefficient times off all established penetrating cryoprotectants, with the possible exception
of glycerol [175].
In connection with its ability to transition membranes, DMSO has further modulating effects on cell membrane
permeability. In contrast to other cryoprotectants, DMSO is unique in dehydrating the phospholipid headgroups
while raising the membrane phase transition temperature [176]. Even the quickly permeating glycerol seems to exert
a very different hydrogen-bonding capability by increasing the repulsive forces between bilayers [177].
In turn, much of the damage related to cryopreservation is linked to membrane integrity. DMSO reduces
membrane rigidity and, at high concentrations, induces pore formation, a mechanism presumed to contribute to
reduction of mechanical and osmotic stresses during cryo-related cellular swelling and shrinking, tissue perturbation
and ice formation [178]. To modulate membrane rigidity by other means, the amount of unsaturated fatty acids
can be altered in pre-treatment [174] or lipid molecules can be added to the cryo-protective solution [179] (although
the unique action of DMSO on lipid bilayers, for example on liposomes, needs to be considered in comparative
studies) [180]. To induce membrane transition channels or pores, transfection agents like polyethylene glycol and
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PVP have sometimes been added to cryo-protective solutions and have proven effective in comparison with
DMSO [181–183].
Other chilling injuries have been attributed to lipid peroxidation and protein denaturation. Some antioxidant
properties have been attributed to DMSO itself [184,185], specifically its reaction with hydroxyl radicals, producing
methyl radicals, in turn producing ethane, and also undercutting the formation of carbonyl groups [186]. Addition
of a wide variety of antioxidants has been attempted in the formulation of cryoprotectant solutions including
mitragynine, glutathione, curcumin [187,188] including natural compounds [189] and mitochondria-targeted antiox-
idants [190,191]. It has been observed that other antioxidants may have at least equivalent antioxidative potency
compared with DMSO [29]. However, in the specific pursuit of a cryoprotectant solution that emulates the molec-
ular interactions of DMSO as closely as possible, it should be borne in mind that some of these alternatives
(e.g., vitamin E) [192,193] are not known as particular scavengers of hydroxyl radicals.
Further innovations that have been considered in counteracting the results of oxidative damage and other
cryoinjuries include the use of apoptosis inhibitors [194], with a caspase I inhibitor having been adopted into a
commercially available medium (CryoStor CS5N - STEMCELL Technologies), and the use of anti-freeze proteins
(AFP) as a DMSO alternative [195]. Incorporating AFP qualities into polymer design has shown some promise [196];
although cryoprotectant success with polymers goes well beyond the emulation of AFP macroscopic properties.
Nonpenetrating polymers of high molecular weight have long been investigated, not for their capability to replace
DMSO, but to supplement cryoprotection from the extracellular vantage point, by inhibiting ice crystallization
and reducing mechanical damage. For example, for HES, a 6% admixture with 5% DMSO was generally favored
for partially historical reasons [102]. Other polymers derived from natural compounds include gelatin, chitosan or
alginate, all in themselves employed as an addition to, not a substitute for DMSO. However, as more recently
developed polymers have entered the field and it has been suggested that they are a viable substitute for DMSO as
discussed in Section 4 and in the following section.
Known DMSO-free solutions
In the preceding section, we have discussed the theoretical considerations and challenges of replacing DMSO with
other compounds mainly from the perspective of the putative mechanism of action of DMSO as a cryoprotectant.
However, itmay be that for any given purpose the specific effects ofDMSOare not deemed pertinent or important
enough to attempt their emulation. Replacement strategies may instead begin by first looking at evidence whether
the alternative is at least as effective as DMSO.
Table 3 lists such examples of ‘successful’ DMSO-free cryopreservation, irrespective of whether these were aimed
at addressing specific mechanisms of action. In consideration are only those studies that compared a DMSO-free
cryo-protective solution directly to aDMSO-containing solution. Not included are studies that aimed at a reduction
rather than total elimination of DMSO, or studies where the efficacy of the proposed cryo-protective solution was
not experimentally compared with a DMSO-containing solution. Table 3 also excludes the various alternative
solutions advanced only for gametes – it is a long-established tenet of the field that results on cryoprotectant
efficacy and toxicity vary greatly between different cell types and situations, but we can at least summarize that
for a variety of cells which are relevant in regenerative medicine and tissue engineering DMSO-free cryoprotection
has been demonstrated using a number of cryo-protective solutions from ‘traditional and basic’ CPAs like glycerol,
to different sugar combinations and novel polymer gels. Equivalence or superiority was established by a variety
of assays, but often not going much beyond cell survival (which is not always the most conclusive measure) [102].
Further analysis of such solutions will be required in the context of advanced development. However, the ability to
fully assess DMSO-free solutions depends on understanding their chemical compositions. As indicated in Table 4,
a range of DMSO-free CPA are now commercially available, but solution composition is frequently subject to
proprietary information.
Commercial development & regulatory considerations
Commercial preparations of DMSO containing cryoprotectants are now widely available and in use for fi-
nal product formulation in more than 20 cell therapy clinical studies and trials (e.g., NCT00672542 [205],
NCT02467387 [206], NCT02166177 [207], NCT01671072 [208], NCT02500849 [209], NCT02208362 [210],
NCT02028455 [211], NCT02387723 [212], NCT0212988 [213], (Personal Communication from manufacturers
and suppliers of CryStor R© [Biolife, STEMCELL Technologies] and CellBanker R© [Zenoaq, ASMBio]). However,
improved cryoprotectant solutions are urgently needed, in part to address the ever-increasing complexity and di-
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Table 3. Reported successful comparisons of ‘dimethyl sulfoxide-free‘ cryopreservation solutions with dimethyl
sulfoxide-based cryoprotective solutions.
DMSO-free CPA composition DMSO as sole CPA Additives present in both
DMSO-free and DMSO
CPAs
Assay Cell type Ref.
FCS+ 0.5 M sucrose+ 20% glycerol 10% No carrier solution
information
Cell survival Human umbilical cord
tissue
[197]
7.5% PLL, 5% ectoin, 5% dextran 10% DMEM (?) – Cell survival
– Apoptosis
– Proliferation
NK cells [173]
1) 300 mM trehalose, 10% glycerol,
0.01% ectoin
2) 300 mM ethylene glycol, 1 mM
taurine, 1% ectoin
10% Normasol-R™ – Cell attachment
– Differentiation
Jurkat cells
MSC
[198]
32% Pentaisomaltose 20% 4% human serum
albumin, 2 IE/ml heparin
carrier solution (?)
– Cell survival
– Colony growth
– Engraftment
HSC [199]
20% Trehalose 20% 10% FBS, RPMI-1640 Cell survival GLC-82 [200]
6,8,10% l-carnitine 6% 10% FBS, RPMI-1640
DMEM- depending on cell
type
– Cell survival
– Proliferation
MCF-7
NIH-3T3
[200]
1) 10% PVP40,
2) 0.05 M glucose, 0.05 M sucrose, 1.5 M
ethylene glycol
10% 10% FBS, ADMEM – Apoptosis
– Cell survival
– Differentiation
– Phenotyping
Human MSC [126]
1-10% Betaine 1-20% +Trehalose 10% FBS, medium (?) Cell survival Hela
GLC-82
MCF-10
[201]
Nil 10% 1-20% Trehalose, 10% FBS,
medium (?)
Cell survival Hela
GLC-82
MCF-10
[201]
200 mmol/l Trehalose, 200 mg/l
cholesterol, 30% PVP40, Lecithin
10% 10% serum, RPMI-1640 – Morphology
– Apoptosis
Sheep ovar [182]
5% HES 10% 10% serum,
DMEM-medium
– Cell survival
– Proliferation
– Differentiation
Human MSC [102]
25% PLL 10% 10% PVA–gelatin (ratio
9:1, w:w),
10% serum,
HEPES-buffered
RPMI-medium
Cell survival Vascular smooth muscle
cells
Endothelial cells
[202]
1) 1% proline, 10% ectoin,
2) 5% proline, 5% ectoin,
3) 10% proline, 10% ectoin,
4) Biofreeze (Biochrom)
10% 1% methycellulose in PBS – Cell survival
– Differentiation
Human MSC [203]
1) 10 uM ROCK inhibitor,
2) 2.5% PEG,
3) 10 uM ROCK inhibitor, 2.5% PEG
10% No carrier solution
information
– Cell survival
– Colony Formation
– Apoptosis
hESC [181]
5-20% PLL 10% DMEM-medium Cell survival L929 [204]
7.5% PLL 10% DMEM-medium – Cell survival
– Differentiation
MSC [204]
FBS: Fetal bovine serum; hESC: Human embryonic stem cells; MSC: Mesenchymal stem cell; NK: Natural killer; PBS: Phosphate-buffered saline; PLL: ε-poly-L-lysine.
versity of cell-based products, but also other aspects of regenerative medicine including the preservation of complex
tissues and organs. Publication of preservation media compositions and results in clinical trials (as in the examples
above) will be crucial to promoting efficient and safe development of cell therapies. However, the main driver of
the field remains the fertility sector and innovation by trial and error during in-house protocol development.
While there has long been talk in the field of employing classical drug screening, discovery and designmethodolo-
gies to cryoprotectant development, these methods are still uncommon and in their infancy. Cell cryopreservation
in 96-well tissue culture trays has been demonstrated for several cell types [132,174,214], but not yet scaled to 384-well
plates more commonly used in high-throughput screening. Differential evolution algorithms [198] and quantitative
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Table 4. Commercially available dimethyl sulfoxide-free cryoprotective reagents, with indications of GMP status and
availability for clinical application.
Name Company Replacement CPA Reported GMP status Description
PRIME-XV R© FreezIS DMSO-Free Irvine Scientific Not disclosed ‘cGMP’ Drug Master File
registration
– For MSC only
– Animal-free,
– Chemically defined
FREEZEstem™ BioLamina Not disclosed ‘GMP-compliant’
ISO13485
– Serum free
– Xeno free
STEM-CELLBANKER R© ‘GMP
grade’ (NB DMSO free
‘GMP-grade’ version
manufactured since 2015)
Zenoaq Resource (supplier
Amsbio)
1,2-dihydroxypropane serum
Glucose
Polymer
Drug Master File (US)
‘GMP-grade’
– Chemical defined
– Animal free
– Xeno free
ReproCryo RM Reprocell Not disclosed R&D only (NB the DMSO free
version is not manufactured in
a GMP-compliant facility)
Drug Master File (JP)
– Xeno free
– Chemically defined
CryoNovo™ P24 Akron Biotech Not disclosed R&D only
Raw material to Pharmacopeia
(US, EP, JP)
– Serum free
– Xeno free
CryoSOfree™ DMSO-free
Cryopreservation Medium
Sigma ε-poly-L-lysine R&D only – Chemically defined
– Animal free
pZerve™
Cryopreservation solution
Sigma Not disclosed R&D only – Chemically defined
– Animal free
CryoNovo™ X12 Akron Biotech Not disclosed R&D only – Serum free
– Xenofree
StemCell Keep Funakoshi Not disclosed R&D only – Serum free
– Xenofree
CryoScarless DMSO-free Funakoshi Not disclosed R&D only – Protein free
– Serum free
ReproCryo DMSO FreeTM Reprocell Not disclosed R&D only – Xenofree
– Chemically defined
Ibidi Freezing Medium
DMSO-free
Ibidi Not disclosed R&D only – Serum free
Biofreeze Biochrom GmbH Not disclosed R&D only – Animal free
– Serum free
Bambanker DMSO Free Nippon Genetics Not disclosed R&D only – Serum free
GMP: Good manufacturing practice; R&D: Research & development.
structure–activity relationship (QSAR) models have been employed [174], but use of functional relationship models
has not yet been widely reported.
Recently, there has been a marked influx of several novel commercial cryoprotectants, many specifically aimed
at the regenerative medicine market, that are marketed ‘DMSO-free’ (Table 4). These products are now beginning
to be used in clinical studies and trials for cell therapy. It is important to be careful in the process of qualification
for such materials to ensure they are suitable for use in manufacture of products for use in humans: a label of
‘GMP-grade’ will not be sufficient to assure adequate quality and safety for new applications. In fact, the term
‘GMP-grade’ is not recognized by regulators and raw materials typically cannot be certified by a regulator as made
to GMP. Any raw material publicized as ‘GMP-grade’ will require considerable interrogation of the supplier to
establish what their statement actually means (n.b. DMSO can be manufactured as a GMP therapeutic product
in its own right, it is not then necessarily intended to be used as a raw material). The construction of a dossier of
information, including manufacturing processes, testing and risk assessment, is an important first step in checking
the suitability of a new CPA for use in humans. Where such dossiers have already been evaluated by regulatory
authorities (such as in a drug master file) this adds confidence that the CPA will be acceptable but does not
necessarily preclude the need for a case-by-case evaluation for each new product. Currently, reagent suppliers are
utilizing a number of approaches including CE Marking and ISO13485 compliance to demonstrate suitability,
although these are more typically used for medical devices. Useful guidance has been published in the United
States Pharmacopeia (USP) (USP 1043, Ancillary materials for cell, gene and tissue-engineered products) and the
European Pharmacopeia (EP) 5.2.12 for raw materials of biological origin. Manufacturers will need to understand
how best to utilize such approaches for their own cell therapy products. There are significant challenges on the path
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Validation of the manufacturing/
cryopreservation procedure (toxicity
and safety studies of CPA solutions 
and components)
Automation (device-assisted methods)
Closed system
Materials and components suitable for
manufacture of GMP products
Clinically accepted (pharmaceutical
grade or medical device certified)
washing solutions
Components of CPA solutions suitable
for manufacture of GMP products
or
Standardization and certification of
CPA solution as class 3 medical device
High flexibility in choosing the
methods of CPA removal
(centrifugation, microfluidics,
filtration)
High flexibility in choosing the
composition of the diluent (any
saline solution with or without
supplements)
Washing out the
CPA solution
before application
Supplementation
of CPA solution
by different
compounds
Replacement of
DMSO in
CPA solution by
different compounds
Removal
Reduction
Replacement
D
M
S
O
 to
xi
ci
ty
Research-application
opportunities
Clinical-application
challenges*
Available research-grade
supplements/replacers
The 3Rs of DMSO toxicity elimination
Sugars (glucose, dextrose, trehalose,
sucrose)
Macromolecules (albumin, HES)
Polymers (PEG, PVP, PLL)
Antifreeze proteins and 
bio-compatible solutes (proline, 
ectoine)
Antioxidants and anti-apoptotic
agents
Figure 1. Options to consider when developing cryoprotective agent strategies to minimize concerns around including dimethyl
sulfoxide as an additive. These comprise ‘3 Rs’ – removal (by dilution or washout in the thawed cell product); reduction (by lowering the
DMSO concentration in the CPA mixture and adding other secondary CPA such as sugars – often an achievable strategy as long as efficacy
of the thawed product can be maintained); replacement (by developing CPA mixes using a range of solutes avoiding DMSO altogether –
which also raises questions about the efficacy of any new mixture, and whether these solutes have existing regulatory approval for
human application).
*Before actual clinical application there may be extensive work on product development which will require a good understanding of the
specific regulatory requirements for the final cell therapy product and the most applicable standards [215].
CPA: Cryoprotective agent; DMSO: Dimethyl sulfoxide; GMP: Good manufacturing practice; HES: Hydroxyethyl starch; PEG: Polyethylene
glycol; PLL: ε-poly-L-lysine; PVP: Polyvinylpyrrolidone.
from research product to clinical application as outlined in Figure 1. This transition will involve considerable work
on product development which will require a good understanding of the specific regulatory requirements for the
final cell therapy product and the most applicable standards [215].
Such innovation is facilitated because regulatory barriers to marketing a cryoprotectant even as ‘clinical grade’
(n.b. This term is not recognized by regulators) are comparatively low compared with the medical products that
they are aimed to preserve. From a regulatory perspective, cryopreservation is required to ‘not alter the relevant
biological characteristics’ of tissues and cells (see below). This implies that product developers must mitigate for the
challenge of incorporating cryoprotectant effects – as illustrated by the fact that in spite of decades of widespread
use, DMSO is acknowledged to elicit cytotoxicity and other long-term effects on cellular behaviors and these are
still being explored. The consideration that cryoprotectant-related changes to membrane integrity, epigenetics,
cyto-metabolism and proteomics might affect therapeutic mechanisms of action (particularly in those cell therapies
that rely on complex cellular interactivity, ‘paracrine’ or ‘bystander’ effects) is unlikely to be limited to DMSO.
The current Industry practice of not disclosing the exact composition of cryo-protective solutions is a hinderance
to protocol improvement and development of greater understanding of preservation of the complex and diverse
cell-based products.
Recognition of the crucial effect that preservation may have on the quality and safety of cell therapy products is
acknowledged and accommodated within existing regulatory considerations for manufactured biological products.
These considerations have been captured as part of guidance documents dealing with consistency and comparability.
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Consistency of a product from batch to batch is crucial and would also be expected for a preservation stage within
a licensed manufacturing process such as cell banking, preservation of ‘intermediates’ (such as preserved progenitor
cells derived from the original pluripotent stem cell line) and the final product, as well as storage and transportation.
Comparability is the regulatory term used for the requirement to demonstrate that when a process has changed,
such as the type or composition of a CPA, the product has not been affected adversely by that change from quality
and safety perspectives. The manufacturer should consider the need to demonstrate ‘comparability’ between the
product made by the original process and the new methods/materials. Relevant information on performance of a
comparability study is given in the guidance document ICH Q5E [216] which is mutually recognized in EU, US
and Japanese regulation.
For consideration of both consistency batch–batch and comparability after process change, it is also important for
the manufacturer to develop adequate knowledge of the cell preparations they are using and ensure use of suitable
critical quality attributes [217]. This may demand multiple parameters for viability and a panel of biomarkers and
functional assays for the cells involved. This will be important and expected by regulators to give confidence that
the chosen bioanalytics regime will detect changes of significance for safety and efficacy of the final product.
Overall process verification requirements will have implications for how a manufacturer should assess their
cryopreservation methods and is captured in document ICH Q8 [218]. More specifically, the manufacturer should
also consider the composition of CPA solutions and assess the risks from additives or excipients in CPAs. These
risk elements might include, in particular, those of biological origin (notably animal origin with attendant risk of
viral contamination), toxic compounds, allergens, mitogens and particulates. In addition, cryovial material should
be assessed for potentially harmful leachates and particle release. It is also important not to forget the potential
influence of cell culture growthmedia components included with the CPA during cryopreservation, both in terms of
their direct effect on the cells ‘solutions effects’ (see Mazur et al. 1972) [219] as the unfrozen solutes are concentrated
around the cells, and also in terms of what chemical interactions may occur between CPA, media or cryovial
components.
Cryostorage and the potential long-term exposure of cells to CPAs, is also a relevant part of manufacturing
considerations reviewed by regulators. In particular, it is worth noting that EU GMP guidance now includes a new
annex (Annex 15, section 6, ‘Verification of transportation’) which came into effect in 2015 and provides further
guidance useful for cryopreserved products.
General conclusion
The use of DMSO has been important in the successful treatment of many thousands of patients worldwide with
serious conditions such as leukemia, and continues to be present in drug preparations and to provide the CPA
of first choice for the diverse and complex range of novel cellular therapies now being developed. However, the
wide-ranging biological impact of DMSO we have described above, combined with the known adverse reactions
which may occur in patients subjected to DMSO containing preparations, means that a greater selection of CPA
solutions may well be in demand for the future [220]. We have described the commercially available DMSO-free
reagents already on the market and in some cases, already in use in clinical trials of new cell-based medicines. The
possible toxicities and impact on cell behavior will need to be investigated in different therapeutic cell types to
avoid early abandonment of DMSO, only to discover unexpected adverse events arising from the premature uptake
of new lesser-studied and unproven CPAs. The rapid development of novel and combination therapies means that
the search for new CPA molecules will and must continue, as should careful evaluation of their biological impact
in diverse cell types. Knowledge of the nature and diversity of cell populations within cell-based clinical products is
vital if the results of cryopreservation investigations are to be compared and this is particularly true of the so-called
‘MSC’ group, which clearly represents a number of biologically different cell types that may respond differently to
a particular CPA. As a generalization, concerns surrounding DMSO toxicity can also be addressed by considering
the ‘3R’s of DMSO toxicity mitigation’ (Figure 1); removal (after cryopreservation); reduction (using additional
secondary CPA) or replacement (using other CPA to completely avoid DMSO). These strategies should be given
due consideration by anybody developing cryopreservation protocols. In particular, the current challenges being
experienced by developers of combined antibody receptor (CAR) T-cell products may benefit from the use of the
‘DMSO 3Rs’ or alternative CPAs outlined in this review.
The development of new CPAs will require more sophisticated high-throughput screening systems and possibly
establishment of model cell systems for a range of cell types as proposed by Stacey et al. [220]. However, few drugs
or clinical interventions are risk free and it is highly likely, that with the availability of refined combination CPAs
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and automated DMSO removal devices, DMSO will continue for the foreseeable future, to contribute to the roll
out of life saving interventions for an increasing range of cell-based medicines.
Future perspective
Over the past decade, there have been many comments recorded about possible negative implications of the use
of DMSO as a cryoprotectant, and exhortations made to find replacements. We fully support continued objective
research into these topics and robust audit of current cryopreservation practices where DMSO is used. However,
in parallel it must be recognized that at the present time, the vast majority of applied cryopreservation practices
depend upon the efficacy provided by DMSO for high functional capacities after thawing. The development
of new CPAs will require more sophisticated high-throughput screening systems and possibly establishment of
model cell systems for a range of cell types as proposed by Stacey et al. [220]. Many of the novel cryoprotectants
appearing in research publications have not progressed to widespread uptake or regulatory approval at the current
time but they will provide invaluable signposts to how to better assess both efficacy and biological impacts of all
cryoprotectants (including DMSO) moving forward. However, few drugs or clinical interventions are risk free
and it is highly likely, that with the availability of refined combination CPAs to lower DMSO concentrations,
and automated DMSO removal devices, DMSO will continue for the foreseeable future to contribute to the roll
out of life saving interventions for an increasing range of cell-based medicines, and improved cell cryo-banking in
high-value biotechnologies.
Executive summary
A key limiting step in the development of novel advanced cell therapies is having the ability to store & ship
cell-based medicines in a viable yet stable state
• Shipment of nonfrozen materials is challenging, and local manufacture of a cell therapy requires demonstration
of product comparability at different manufacturing sites.
• The diversity and complexity of cell therapies therefore demands new cryopreservation methodologies and
cryoprotectants.
Dimethyl sulfoxide has been the cryoprotectant of choice for most animal cell cryopreservation protocols since the
early history of cryopreservation technology
• Clinical experience in transplantation and transfusion over more than 40 years has shown that dimethyl sulfoxide
(DMSO) can be used safely and effectively.
• Nevertheless, it can affect the phenotype and genotype for both mammalian and nonmammalian cells and
exhibit apparent toxicity in patients, which is driving the search for less cytotoxic cryoprotectants.
In this review, we evaluate the history of clinical use of DMSO & seeks to explain the 3Rs for use of DMSO:
reduction, removal & replacement
• We consider the adverse events that may be associated with the toxicity of DMSO in the context of its
effectiveness, reviewing the real incidence of adverse effects in patients and the probable causes.
• We review the key approaches already in use as a means of reducing its toxic effects by reduction of DMSO
concentration, removal of DMSO from cell preparation post-thaw and alternative cryoprotectants are considered
and assessed in terms of their progression to suitability for clinical use.
Conclusion
• DMSO has long served to enable cells to be stored for future use and continues to be the cryoprotectant of first
choice.
• Replacement cryoprotectants are being developed but are yet to make significant impact in cell therapies.
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